Compositions and Methods for Treating Injuries to the Visual System of a Human
OwnerKhizer Khaderiinventor
Life of this patent
Estimating the term…
Abstract
Methods and compositions for treating injuries to the neural system of a human eye and corresponding structures in the brain are designed to degrade gylcosaminoglycans (GAGs) within chondroitin sulphate proteoglycans (CSPG) using chondroitinase ABC (cABC), preserving neural architecture and protecting the visual system from progressive damage after vascular insult of the optic nerve and/or other portions of the visual system. The methods include delivering the cABC composition by topically applying the composition onto the patient's cornea, stereotactic injections into the related anatomy, delivery by micro-osmotic pumps, delivery by nanoparticles and/or nanocapsules, and delivery through intravitreal implants.
Claims20
A method of treating a patient suffering from a condition adversely affecting the patient's visual system comprising administering to the patient a composition comprising chondroitinase ABC (cABC), wherein said administration of said composition to said patient has at least one of an anti-inflammatory, neuroprotective and/or neuroplasticity therapeutic effect on the visual system.
A method of treating a patient suffering from a condition adversely affecting the patient's visual system comprising administering to the patient a composition comprising chondroitinase ABC (cABC) wherein the administration of the composition to the patient has at least one of an anti-inflammatory, neuroprotective and/or neuroplasticity therapeutic effect on at least one of the patient's cornea, anterior chamber, iris, pupil, ciliary body, lens, vitreous humor, retina, choroids, optic nerve, optic chiasm, optic tract, lateral geniculate nuclei, optic radiations, visual cortex, or visual association cortex and wherein the composition comprises cABC in an amount of 1-100,000 units and wherein the composition comprises cABC concentrated in a range from 50 to 500 units/mL in a buffering solution.
A composition effective to treat a patient suffering from a condition adversely affecting the patient's visual system, wherein said composition comprises chondroitinase ABC (cABC) in an amount of 1-100,000 units concentrated in a range from 50 to 500 units/mL in a buffering solution and wherein the administration of the composition to the patient has at least one of an anti-inflammatory, neuroprotective and/or neuroplasticity therapeutic effect.
Dependencies are inferred from the claim text.